Mesoblast
Mesoblast is a leader in the development of innovative cellular medicines based on its proprietary mesenchymal lineage adult stem cell technology. The company focuses on developing treatments for inflammatory diseases, cardiovascular diseases, and orthopedic conditions. Mesoblast's unique value lies in its extensive intellectual property portfolio and its ability to manufacture allogeneic cellular medicines at scale.
Short position
Mesoblast (ASX:MSB) has 7.57% of its shares on issue reported as short positions as of 5 Oct 2026, or about 98,260,040 shares. Over the past 30 days that figure has risen 0.64 percentage points, and over 90 days it has fallen 0.78 percentage points. Its highest recorded short interest was 11.00% in October 2015. MSB is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4Mesoblast (MSB) company profile
Profile, insiders and operations
Company
AI-generated research profile of Mesoblast
MSB intelligence dossier
Public-source evidence for this company, with industry drill-up links.
- Tax paid and taxable income records
- Government contracts and public money
- Emissions and trade exposure
- Political donations and lobbying links